Determining the effect of new antiviral (Direct-Acting Antivirals; DAAs) medicines, such as SOF + DCV on HCV treatment in HIV/HCV co-infected patients. HIV/HCV co-infected patients were treated with SOF + DCV combination for 12 weeks and the drug dosage was adjusted according to ART in case needed. APRI, FIB4 Index and MELD Score formulas were used to examine the effect of treatment on the degree of liver fibrosis and HCV RNA PCR was performed to evaluate the response to 12-week treatment after the completion of the treatment. Twenty-four male patients with the mean age of 44±7.73 years were enrolled in the study with 58.3% having a history of unprotected sexual contact and 100% having a history of injectable drug use. The mean HCV viral load at the baseline was 6.3Log10 IU/ML and 5 cases having undetectable viral load were excluded. Seven patients had GT1, 6 patients had GT3 and other cases were not detectable. HCV RNA PCR was undetectable in 18 patients 12 weeks after the treatment. Moreover, the decrease in ALT and AST (P= 0.001), the increase in platelet count (P= 0.016), and the increase in cr (P= 0.032) were significant, which partially justified the reduction in liver fibrosis using non-invasive methods. Twelve weeks after treatment, 19 patients were tested for HCV RNA PCR, the HCV viral load was not detectable in 18 patients and reached to SVR12 (sustained virologic response) rate 94.7%. According to the current study, treatment with SOF + DCV combination was associated with SVR12 rate 94.7%. Thus, SOF + DCV combination can now be used as an effective medicine in the treatment of all hepatitis C genotypes in HIV/HCV co-infected patients.
Background Prostate-specific antigen (PSA) is a serine protease that is secreted by prostate cells and it is useful as a tumor marker for prostate cancer. Objectives In this study, the relationship between some of metabolic factors and serum PSA level was investigated. Materials and Methods In this cross-sectional study, patients with urinary symptoms or for screening of the prostate cancer (after 50 years of age or 40 years with a family history of prostate cancer), were evaluated. Collected data included metabolic syndrome factors such as cholesterol (Chol), triglycerides (TG), fasting blood sugar (FBS), and body mass index (BMI), serum PSA level, prostate volume and age. Results 481 patients were enrolled to this study with the average age of 60.69 ± 9.72 years and the average PSA level of 1.70 ng/ml. Data analysis showed that there was a significant relationship between serum PSA level with age (P < 0.001, r = 0.30) and prostate volume (P < 0.001, r = 0.29). There were not significant relationship between serum PSA level with TG (P = 0.57, r = 0.026), Chol (P = 0.57, r = -0.025), FBS (P = 0.054, r = 0.088), and BMI (P = 0.89, r = 0.006). Conclusions This study showed that, with increasing age and prostate volume, serum PSA level increased, and an increase in the levels of cholesterol, TG, FBS and BMI did not have significant effect on serum PSA level.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.